Clexio Biosciences Ltd.
- Biotech or pharma, therapeutic R&D
Clexio Biosciences is a clinical stage neuropsychiatry-focused company. Our pipeline includes:
- CLE-100 (oral esketamine), currently in Ph2 studies for treating MDD
- CLE-905, an M1/M4 agonist program which just completed IND-enabling studies
- CLE-901, an NMDA antagnosit being developed for MDD, soon to start IND-enabling studies
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}